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brain metastases (BMs) with only modest improvement of 
overall survival. 
Materials and Methods: To evaluate the impact of PCI on 
survival we reviewed 179 LD SCLC patients treated with 
definitive chemoradiotherapy (CRT) in the concurrent or 
sequential setting. PCI was applied in the partial and 
complete responders exclusively provided contrast-enhanced 
cranial magnetic resonance imaging (cMRI) before and after 
primary treatment showed no signs of occult BMs. Correlation 
between PCI and time to progression (TTP) as well as overall 
survival (OS) was analysed. Kaplan-Meier analysis, uni- and 
multivariate Cox regression were used to describe survival 
within subgroups defined by treatment response and 
application of PCI. 
 
Results: Concurrent and sequential chemoradiotherapy CRT 
was applied in 71 (40%) and 108 (60%) patients, respectively. 
In 58 (32%) patients metachronous BMs were detected. PCI 
was applied in 71 (39%) patients. 15 patients developed BMs 
after PCI. Median TTP and OS in responders treated with PCI 
were 812 and 801 compared to 355 (range: 284 - 456) (p < 
0.0001, log-rank test) and 385 (range: 318 – 452) (p < 0.0001, 
log-rank test) days in the rest of the patient cohort. In 
multivariate analysis, application of PCI in treatment 
responders comprehensively staged with cMRI was a variable 
that significantly correlated with TTP (HR 2.16 CI HR 1.37-
3.42, p < 0.001) and OS (HR 1.89 CI HR 1.37-2.63, p < 0.0001) 
after adjustment of other patient- and treatment-related 
factors. 
 
Conclusion: In this LD SCLC patient cohort comprehensively 
staged with cMRI, achievement of maximum treatment 
response and application of PCI significantly affects time to 
progression and overall survival. 
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Purpose or Objective: Preoperative chemoradiotherapy 
(CRT) has been established as the standard treatment for T3-
4 rectal cancers. In a phase II trial, we reported limited 
toxicity and excellent local control using image-guided and 
intensity-modulated RT (IG-IMRT) with a simultaneous 
integrated boost (RTSIB) instead of concomitant 
chemotherapy. The present multicentric randomized trial 
compares this strategy to CRT. In addition, the neutrophil-
to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were 
examined as a prognostic immunoscore in a subset of 
patients. 
 
Materials and Methods: cT3-4 rectal cancer patients were 
randomly assigned to receive either preoperative IG-IMRT 
46Gy/23 fractions plus capecitabine 825 mg/m2 twice daily 
(CRT-arm) or IG- IMRT 46Gy/23 fractions with a SIB to the 
rectal tumor up to a total dose of 55.2 Gy (RTSIB- arm). 
Metabolic tumor activity reduction, by measuring the 
percentage of SUVmax difference (Response Index = RI) on 
sequential 18-fluorodeoxyglucose positron emission 
tomography (FDG-PET), was the primary endpoint. We 
assessed whether RTSIB was non-inferior to CRT with a non-
inferiority margin of -10% for RI. 
 
Results: A total of 174 patients were randomly assigned to 
the CRT-arm (n=89) or RTSIB- arm (n=85). A consort flow 
diagram is presented in Figure 1. The RI difference between 
RTSIB and CRT was -2.9% (95% CI, -10.1% to 4.3%). The ypCR 
rate was 24% with CRT compared to 14% with RTSIB (p=0.13). 
There was no significant difference in sphincter preservation 
(75% vs 68%, p=0.29). The R0 resection rate was 98% in the 
CRT-arm and 97% in the RTSIB-arm. Acute grade 3 toxicity 
was 6% and 4% in the CRT- and RTSIB-arm, respectively. A 
detailed analyses of early adverse events is shown in Table 1. 
The highest quartiles of NLR and CRP identified high-risk 
patients in terms of disease free and overall survival. 
 
 
 
 
Conclusion: Preoperative CRT is well tolerated when IG-IMRT 
is used. RTSIB represents an attractive alternative to CRT for 
patients with a contra-indication for chemotherapy. The 
immunological landscape of colorectal cancer shapes novel 
possibilities for risk assessment. 
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